NCT04318886
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 21 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must be diagnosed within past 60 days of initial pre-screening with an advanced cancer, defined as metastatic and/or recurrent/progressive stage III/IV cancer
Exclusions: Patients receiving hospice care
https://ClinicalTrials.gov/show/NCT04318886